This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis

This study has been completed.
Sponsor:
Collaborator:
Exalenz Bioscience LTD.
Information provided by (Responsible Party):
Virginia Commonwealth University
ClinicalTrials.gov Identifier:
NCT01157845
First received: July 2, 2010
Last updated: April 29, 2014
Last verified: April 2014
  Purpose
The methacetin breath test (MBT) is a non-invasive liver function test which measures the ability of the liver to metabolize a tracer dose of a compound to carbon dioxide, which is exhaled. The study hypothesis is that measurement of the MBT will allow earlier detection of a decline in liver function in patients with cirrhosis who are awaiting liver transplantation.

Condition Intervention Phase
Cirrhosis Device: BreathID (Methacetin breath test) Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Use of the BreathID Methacetin Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Patients Awaiting Liver Transplantation

Resource links provided by NLM:


Further study details as provided by Virginia Commonwealth University:

Primary Outcome Measures:
  • Mortality From Liver Failure [ Time Frame: 1 year ]
    Patient dies of liver-related causes within 1 year of study entry


Secondary Outcome Measures:
  • Liver Transplantation [ Time Frame: 1 year ]
    Patient experiences complications of liver failure within 1 year of study entry and undergoes liver transplantation


Enrollment: 165
Study Start Date: March 2010
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Laboratory assay Device: BreathID (Methacetin breath test)
13C-labeled methacetin (75 mg) is given to the patient by mouth in a small volume of water, and expired 13C-labeled carbon dioxide is measured from a nasal cannula.
Other Name: BreathID (Exalenz Bioscience LTD)

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Being considered for placement or already on the liver transplantation waiting list
  2. Cirrhosis caused by any cause of chronic liver disease.
  3. Age > 18 years

Exclusion criteria:

  1. Known or suspected hepatocellular carcinoma
  2. Prior TIPS placement
  3. Severe congestive heart failure
  4. Severe pulmonary hypertension
  5. Uncontrolled diabetes mellitus (HBA1C >9.5%)
  6. Any autoimmune disorder, which is currently being treated with prednisone or any other immune suppressive medication.
  7. Previous surgical bypass surgery for morbid obesity (BMI >45)
  8. Extensive small bowel resection
  9. Patients currently receiving total parenteral nutrition if they have contraindications to oral drugs
  10. Women who are pregnant
  11. Patients who are allergic to acetaminophen/ paracetamol or any other related medications
  12. Patients with an acute current exacerbation of chronic obstructive pulmonary disease or bronchial asthma.
  13. Patients that are taking hepatotoxin drugs
  14. Patient, based on the opinion of the investigator, should not be enrolled into this study
  15. Patient is unable or unwilling to sign informed consent.
  16. Patients that are participating in other clinical trials evaluating experimental treatments or procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01157845

Locations
United States, Michigan
Henry Ford Health System
Detroit, Michigan, United States, 48202
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
United States, Virginia
Virginia Commonwealth University Medical Center
Richmond, Virginia, United States, 23298
Israel
Hadassah Medical Center
Jerusalem, Israel, 91120
Sponsors and Collaborators
Virginia Commonwealth University
Exalenz Bioscience LTD.
Investigators
Principal Investigator: Richard T Stravitz, MD Virginia Commonwealth University
  More Information

Publications:
Responsible Party: Virginia Commonwealth University
ClinicalTrials.gov Identifier: NCT01157845     History of Changes
Other Study ID Numbers: VirginiaCU HM12041
Study First Received: July 2, 2010
Results First Received: January 17, 2014
Last Updated: April 29, 2014

Additional relevant MeSH terms:
Fibrosis
Liver Cirrhosis
Pathologic Processes
Liver Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on August 18, 2017